Deirdre K Tobias1, Patrick R Lawler1, Paulo H Harada1, Olga V Demler1, Paul M Ridker1, JoAnn E Manson1, Susan Cheng1, Samia Mora2. 1. Division of Preventive Medicine, Department of Medicine (D.K.T., P.H.H., O.V.D., P.M.R., J.E.M., S.C., S.M.), Center for Lipid Metabolomics (P.H.H., O.V.D., S.M.), Division of Cardiovascular Medicine (P.M.R., S.C., S.M.), Mary Horrigan Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA (J.E.M.); Peter Munk Cardiac Centre, University Health Network, and Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, ON, Canada (P.R.L.); Center for Clinical and Epidemiological Research, Hospital Universitario at University of Sao Paulo, Brazil (P.H.H.); and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (J.E.M.). 2. Division of Preventive Medicine, Department of Medicine (D.K.T., P.H.H., O.V.D., P.M.R., J.E.M., S.C., S.M.), Center for Lipid Metabolomics (P.H.H., O.V.D., S.M.), Division of Cardiovascular Medicine (P.M.R., S.C., S.M.), Mary Horrigan Connors Center for Women's Health and Gender Biology, Brigham and Women's Hospital & Harvard Medical School, Boston, MA (J.E.M.); Peter Munk Cardiac Centre, University Health Network, and Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, University of Toronto, ON, Canada (P.R.L.); Center for Clinical and Epidemiological Research, Hospital Universitario at University of Sao Paulo, Brazil (P.H.H.); and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (J.E.M.) smora@bwh.harvard.edu.
Abstract
BACKGROUND: Circulating branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) are strong predictors of type 2 diabetes mellitus (T2D), but their association with cardiovascular disease (CVD) is uncertain. We hypothesized that plasma BCAAs are positively associated with CVD risk and evaluated whether this was dependent on an intermediate diagnosis of T2D. METHODS: Participants in the Women's Health Study prospective cohort were eligible if free of CVD at baseline blood collection (n=27 041). Plasma metabolites were measured via nuclear magnetic resonance spectroscopy. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for BCAAs with incident CVD (myocardial infarction, stroke, and coronary revascularization). RESULTS: We confirmed 2207 CVD events over a mean 18.6 years of follow-up. Adjusting for age, body mass index, and other established CVD risk factors, total BCAAs were positively associated with CVD (per SD: HR, 1.13; 95% CI, 1.08-1.18), comparable to LDL-C (low-density lipoprotein cholesterol) with CVD (per SD: HR, 1.12; 95% CI, 1.07-1.17). BCAAs were associated with coronary events (myocardial infarction: HR, 1.16; 95% CI, 1.06-1.26; revascularization: HR, 1.17; 95% CI, 1.11-1.25), and borderline significant association with stroke (HR, 1.07; 95% CI, 0.99-1.15). The BCAA-CVD association was greater (P interaction=0.036) among women who developed T2D before CVD (HR, 1.20; 95% CI, 1.08-1.32) versus women without T2D (HR, 1.08; 95% CI, 1.03-1.14). Adjusting for LDL-C, an established CVD risk factor, did not attenuate these findings; however, adjusting for HbA1c and insulin resistance eliminated the associations of BCAAs with CVD. CONCLUSIONS: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
BACKGROUND: Circulating branched-chain amino acids (BCAAs; isoleucine, leucine, and valine) are strong predictors of type 2 diabetes mellitus (T2D), but their association with cardiovascular disease (CVD) is uncertain. We hypothesized that plasma BCAAs are positively associated with CVD risk and evaluated whether this was dependent on an intermediate diagnosis of T2D. METHODS:Participants in the Women's Health Study prospective cohort were eligible if free of CVD at baseline blood collection (n=27 041). Plasma metabolites were measured via nuclear magnetic resonance spectroscopy. Multivariable Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for BCAAs with incident CVD (myocardial infarction, stroke, and coronary revascularization). RESULTS: We confirmed 2207 CVD events over a mean 18.6 years of follow-up. Adjusting for age, body mass index, and other established CVD risk factors, total BCAAs were positively associated with CVD (per SD: HR, 1.13; 95% CI, 1.08-1.18), comparable to LDL-C (low-density lipoprotein cholesterol) with CVD (per SD: HR, 1.12; 95% CI, 1.07-1.17). BCAAs were associated with coronary events (myocardial infarction: HR, 1.16; 95% CI, 1.06-1.26; revascularization: HR, 1.17; 95% CI, 1.11-1.25), and borderline significant association with stroke (HR, 1.07; 95% CI, 0.99-1.15). The BCAA-CVD association was greater (P interaction=0.036) among women who developed T2D before CVD (HR, 1.20; 95% CI, 1.08-1.32) versus women without T2D (HR, 1.08; 95% CI, 1.03-1.14). Adjusting for LDL-C, an established CVD risk factor, did not attenuate these findings; however, adjusting for HbA1c and insulin resistance eliminated the associations of BCAAs with CVD. CONCLUSIONS: Circulating plasma BCAAs were positively associated with incident CVD in women. Impaired BCAA metabolism may capture the long-term risk of the common cause underlying T2D and CVD.
Authors: Paul M Ridker; Nancy R Cook; I-Min Lee; David Gordon; J Michael Gaziano; Joann E Manson; Charles H Hennekens; Julie E Buring Journal: N Engl J Med Date: 2005-03-07 Impact factor: 91.245
Authors: W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer Journal: Am J Epidemiol Date: 1985-07 Impact factor: 4.897
Authors: Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey Journal: Cell Metab Date: 2009-04 Impact factor: 27.287
Authors: D Preiss; N Rankin; P Welsh; R R Holman; A J Kangas; P Soininen; P Würtz; M Ala-Korpela; N Sattar Journal: Diabet Med Date: 2016-03-03 Impact factor: 4.359
Authors: Ranee Chatterjee; Clemontina A Davenport; Lydia Kwee; David D'Alessio; Laura P Svetkey; Pao-Hwa Lin; Cris A Slentz; Olga Ilkayeva; Johanna Johnson; David Edelman; Svati H Shah Journal: Metabolomics Date: 2020-06-18 Impact factor: 4.290
Authors: Ryoko Katagiri; Mingyang Song; Xuehong Zhang; Dong Hoon Lee; Fred K Tabung; Charles S Fuchs; Jeffrey A Meyerhardt; Reiko Nishihara; Andrew T Chan; Amit D Joshi; Motoki Iwasaki; Shuji Ogino; Walter C Willett; Edward Giovannucci; Kana Wu Journal: Cancer Prev Res (Phila) Date: 2019-11-07
Authors: Raji Balasubramanian; Olga Demler; Marta Guasch-Ferré; Nina P Paynter; Ryan Sheehan; Simin Liu; JoAnn E Manson; Jordi Salas-Salvadó; Miguel Á Martínez-Gonzalez; Frank B Hu; Clary Clish; Kathryn M Rexrode Journal: Circ Genom Precis Med Date: 2020-11-03
Authors: Wenyi Wang; Ko Willems van Dijk; Carolien A Wijsman; Maarten P Rozing; Simon P Mooijaart; Marian Beekman; P Eline Slagboom; J Wouter Jukema; Raymond Noordam; Diana van Heemst Journal: Metabolomics Date: 2021-06-09 Impact factor: 4.290